Cannabigerol (CBG): The daily dose will consist of 50 mg of CBG. Blood tests will be conducted at Baseline, Week 2, Week 4, Week 6, and Week 8 to monitor inflammatory markers and immune response. Self-reported questionnaires will be completed at Baseline, Week 4, and Week 8 to assess symptoms and quality of life.
Study summary
This is a single-group exploratory longitudinal prospective study lasting 8 weeks. The study aims to measure the efficacy of purified cannabigerol (CBG) in patients with active rheumatoid arthritis using laboratory and self-reported outcome measures.
Eligibility
Sex
ALL
Min age
25 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Male or female, over 25 years of age
* Positive anti-CCP blood test
* Active RA-related inflammation with at least 2 swollen joints
* University graduate
* Generally healthy with no uncontrolled chronic disease
* Able to read, understand, and sign informed consent
* Resides in the USA
* Willing to comply with study requirements and avoid other cannabis products during the study period
Exclusion Criteria:
* Pre-existing chronic conditions preventing adherence
* Severe allergic reactions requiring an Epi-pen
* Use of opiates in the last 4 weeks or cannabis in the last 8 weeks
* Pregnant or breastfeeding women
* Recent invasive medical procedure or surgery
* Active malignancy or ongoing oncology treatment
* Use of cytochrome P450 or 3A4 inhibitors
* History of substance abuse
Primary outcome measure(s)
Change in inflammatory markers from Baseline to Week 8 — Baseline, Week 2, Week 4, Week 6, and Week 8 Measurement of blood levels of ESR (Erythrocyte Sedimentation Rate), CRP (C-Reactive Protein), IL6 (Interleukin 6), and TNFa (Tumor Necrosis Factor-alpha) at Baseline, Week 2, Week 4, Week 6, and Week 8.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.